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Abstract
Background Medical discharge management of acute coronary
syndromes (ACS) remains suboptimal outside randomised trials
and constitutes an essential quality benchmark for ACS. We
sought to evaluate the rates of key guideline-recommended
pharmacological agents after ACS and characteristics associated
with optimal treatment at discharge.
Methods The Rijnmond Collective Cardiology Research
(CCR) registry is an ongoing prospective, observational study
in the Netherlands that aims to enrol 4000 patients with ACS.
We examined discharge and 1-month follow-up medication
use among the first 1000 patients enrolled in the CCR registry.
Logistic regression was performed to identify patient and
hospital characteristics associated with collective guideline-
recommended pharmacotherapy at hospital discharge.
Results At discharge, 94% of patients received aspirin, 100%
thienopyridines, 80 % angiotensin-converting enzyme
inhibitors/angiotensin-II receptor blockers, 87 % β-blockers,
96 % statins, and 65 % the combination of all 5 agents. ST-
segment elevation myocardial infarction, hypertension, hyper-
cholesterolaemia, and enrolment in an interventional centre
were positive independent predictors of 5-drug combination
therapy at discharge. Negative independent predictors were
unstable angina and advanced age.
Conclusion Current data from the CCR registry reflect a high
quality of care for ACS discharge management in the
Member hospitals are listed in Appendix A.
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Rotterdam-Rijnmond region. However, potential still remains
for further optimisation.
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Introduction
Acute coronary syndrome (ACS) remains a major cause of
morbidity and mortality in the Western world. Despite the use
of percutaneous coronary intervention (PCI) for acute man-
agement of ACS, patients are still at risk for recurrent cardio-
vascular events [1, 2]. In this regard, antiplatelet agents,
angiotensin-converting enzyme inhibitors (ACE-I) or angio-
tensin II receptor blockers (ARB), β-blockers, and lipid-
lowering agents are individually effective in reducing second-
ary cardiovascular events, and even more effective when
combined together [2].
The guidelines of the European Society of Cardiology on
the management of non-ST-segment elevation acute coronary
syndromes (NSTE-ACS) [3] and ST-segment elevation myo-
cardial infarction (STEMI) [4, 5], as well as the American
College of Cardiology/American Heart Association guide-
lines recommend the collective use of these pharmacological
agents for long-term treatment of patients after ACS [6].
Moreover, the prescription of these classes of agents at dis-
charge is used as performance measures for patients with both
ST-segment elevation and non-ST-segment elevation myocar-
dial infarction [3, 7]. Nevertheless, there is evidence to suggest
that patients with ACS are still not optimally managed with
the aforementioned combination of agents after an acute cor-
onary event [8].
Accordingly, the purpose of the current study was to
determine the individual and collective prescription rates
of the 5 key guideline-recommended therapies (aspirin,
thienopyridines, ACE-I/ARBs, β-blockers, and statins) af-
ter hospital discharge and adherence at 1-month follow-up
in the first subset of 1000 ACS patients from the ongoing
Rijnmond Collective Cardiology Research (CCR) registry.
At the same time, this will serve as a baseline measurement
for discharge management of ACS in our region, an impor-
tant performance indicator of quality of care. We also
sought to evaluate patient and practice characteristics asso-
ciated with the collective use of these agents.
Methods
Study design and population
Full details of the CCR study (Dutch Trial Register unique
identifier: NTR3704) rationale and methodology are reported
in the present issue of the Netherlands Heart Journal [9]
along with the current report. In brief, the CCR study is a
prospective, multicentre, observational registry of manage-
ment practices and outcome of ACS up to 12 months post-
discharge. Eligible patients are (1) ≥18 years of age on
presentation; (2) diagnosed with NSTE-ACS or STEMI
and treated with PCI during index hospitalisation. The only
exclusion criterion is intolerance for aspirin, clopidogrel or
prasugrel. Currently, 11 member sites of the CCR network
in the Rotterdam-Rijnmond region in the Netherlands
(Appendix) are participating in this observational study.
Enrolment will continue until the intended number of
4000 patients is recruited. The CCR registry was initiated
after updating treatment guidelines of the participating net-
work to include prasugrel as the first-line treatment option
for antiplatelet therapy.
Patient characteristics, clinical features, angiographic and
procedural details, and in-hospital outcomes were abstracted
from the medical chart per routine and entered into a secure
web-based and centralised database by enrolling site person-
nel. After the index hospitalisation, patients were routinely
followed up at 1 month and 12months at the outpatient clinics
of the enrolling sites, after which information on medication
use and clinical outcomes was collected and entered into the
central database. In the current study, continued adherence
was assessed by patient report as provided during the 1-
month follow-up visit.
The current study cohort was restricted to the first consec-
utive 1000 ACS patients enrolled in the CCR study who were
alive at 1-month follow-up with complete follow-up data on
discharge medications. These patients were recruited between
August 2011 and February 2012.
Pharmacotherapy
The 5 key guideline-recommended therapies of interest were
aspirin, thienopyridines, ACE-I/ARBs, β-blockers, and
statins. For the purpose of the present analysis, patients were
divided into two subsets: those receiving all 5 pharmacolog-
ical agents at discharge versus patients not receiving the 5-
drug combination.
Ethics
Patients were not subjected to acts or imposed to any mode
of behaviour for the purpose of this study, other than stan-
dard treatment. Therefore, according to Dutch law, written
informed consent for a patient to be enrolled in this study
was not required. All patients provided oral assurance of
their willingness to participate in the current study. This
study is conducted according to the Privacy Policy of the
Erasmus MC and according to the Erasmus MC regulations
for the appropriate use of data in patient-oriented research,
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and is approved by the regional ethics committee (reference
# MEC-2010-417).
Statistical analysis
Continuous variables are summarised as mean ± standard
deviation (SD) or median with interquartile range (IQR),
depending on normal distribution and were compared using
the Student t -test or Mann–Whitney U -test as appropriate.
Categorical variables are summarised as percentages and were
compared using the chi-square test. The McNemar test was
used for pairwise comparisons of discharge and follow-up
medication use. The primary study outcome was the collective
discharge prescription of aspirin, thienopyridines, ACE-I/
ARBs, β-blockers, and statins. Multivariable logistic regres-
sion was performed to identify patient and hospital character-
istics independently associated with the collective use of the
aforementioned 5 evidence-based agents using the forward
selection method. The following candidate variables associat-
ed with the 5-drug combination therapy at discharge on
univariate analyses (p <0.05) were entered into the model:
age, diabetes, hypertension, hypercholesterolaemia, family
history of coronary artery disease, previous coronary artery
bypass grafting (CABG), enrolment into the registry at the
interventional centre, unstable angina (UA), and STEMI.
Model discrimination was evaluated by the c-statistic and
calibration by the Hosmer-Lemeshow goodness-of-fit test.
All analyses were performed using SPSS version 20 (SPSS,
Inc., Chicago, Illinois, USA) and two-tailed P-values<0.05
were considered to indicate statistical significance.
Results
The baseline characteristics of the study cohort are presented
in Table 1. The mean age was 63.7±12.5 years, and 72.2 %
were men. The most commonly documented comorbidities or
risk factors present at the time of admission for the index ACS
event included hypertension, family history of coronary artery
disease, and smoking. Approximately 42 % presented with
Table 1 Baseline demographic
and clinical characteristics
CABG indicates coronary artery
bypass grafting; HF heart failure;
MI myocardial infarction;
NSTEMI non-ST-segment eleva-
tion myocardial infarction; PCI
percutaneous coronary interven-
tion; STEMI ST-segment eleva-
tion myocardial infarction; TIA
transient ischaemic attack; and
UA unstable angina
a Combination therapy is defined
as the collective use of aspirin,
thienopyridines, angiotensin-
converting enzyme inhibitors or













Age, mean (SD) 63.7 (12.5) 62.6 (12.5) 65.9 (12.3) <0.001
Male gender (%) 72.2 72.8 70.9 0.53
Risk factors (%)
- Diabetes 18.3 20.1 14.6 0.04
- Hypertension 50.1 54.9 40.6 <0.001
- Hypercholesterolaemia 36.4 40.2 29.4 0.001
- Current smoker 37.2 38.2 37.5 0.86
- Family history 45.6 50.6 42.7 0.02
Medical history (%)
- Previous MI 19.1 19.6 18.2 0.59
- Previous HF 3.9 3.4 5.1 0.20
- Previous CABG 5.5 4.5 7.6 0.05
- Previous PCI 19.6 19.9 19.0 0.76
- Previous stroke/TIA 7.0 7.0 7.0 0.97
Enrolment in interventional
centre (%)
42.0 46.2 32.9 <0.001
Admission length (days) 4 (3–6) 4 (4–6) 4 (3–7) 0.07
Ejection fraction <0.001
- Normal (≥50 %) 69.0 65.6 76.1
- Moderate (30–49 %) 26.8 31.1 17.7
- Poor (<30 %) 4.2 3.3 6.2
Time from admission to PCI (days) 0 (0–2) 0 (0–2) 1 (0–3) <0.001
Discharge diagnosis (%)
- UA 26.6 21.8 37.0 <0.001
- NSTEMI 31.2 30.1 33.5 0.28
- STEMI 42.2 48.1 29.4 <0.001
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STEMI, 31 % with non-ST-segment elevation myocardial
infarction, and 27 % with UA. A total of 652 ACS patients
(65 %) received all 5 guideline-recommended classes of phar-
macological agents at discharge. These patients were younger,
more likely to have diabetes, hypertension, hypercholesterol-
aemia, and a family history of coronary artery disease, and
more likely to be diagnosed with STEMI and enrolled to the
registry in an interventional centre. In contrast, patients re-
ceiving the collective prescription of aforementioned agents
were less likely to have previous CABG and less likely to be
diagnosed with UA.
Figure 1 depicts the discharge prescription rates and med-
ication use at follow-up in the study cohort according to ACS
spectrum. Institutional discharge and follow-up prescription
rates are presented in Figs. 2 and 3, respectively. At discharge,
94.0 % of the overall study patients were prescribed aspirin,
99.8 % thienopyridines, 8.0 % oral anticoagulants, 80.3 %
ACE-I/ARBs, 87.1 % β-blockers, and 95.5 % statins. There
were marginal numbers of patients discontinuing treatment
and being initiated on treatment after discharge (Table 2).
Overall, the use of aspirin (p =1.00), ACE-I/ARB (p =0.20),
β-blocker (p =0.22), and statin (p =0.50) therapies, as well as
the collective use of the 5 guideline-recommended medica-
tions (p =0.06), were similar at discharge and 1-month follow-
up, whereas the use of thienopyridines declined (p =0.02).
The results of multivariable analysis for the 5-drug combi-
nation therapy at discharge are presented in Table 3. The
model c-statistic and Hosmer-Lemeshow P-values were 0.69
and 0.67, respectively, indicating good discrimination and
calibration.
Discussion
The present study revealed that 65 % of the PCI-treated ACS
patients received all 5 guideline-recommended classes of phar-
macological agents at discharge in the first subset of 1000
patients in the ongoing Dutch CCR registry. Individual
utilisation rates for aspirin, thienopyridine, ACE-I/ARBs, β-
blockers, and statins at hospital discharge were 94 %, 100 %,
80%, 87%, and 96%, respectively, andwere similar at 1-month
follow-up except for thienopyridines. Importantly, STEMI and
UA were the most powerful respective positive and negative
predictors of the use of combination therapy at discharge. The
present utilisation rates of guideline-recommended pharmaco-
logical agents represent current medical discharge management
of ACS in our registry/region and serve as a baseline regional
core measure performance.
Although randomised controlled trials set the ‘gold stan-
dard’ for evaluating treatment efficacy, observational studies
Fig. 1 Medication use at discharge and 1-month follow-up according to
ACS spectrum. *P<0.05. ACE-I/ARB indicates angiotensin-converting
enzyme inhibitor or angiotensin II receptor blocker; ACS, acute coronary
syndrome; NSTEMI, non-ST-segment elevation myocardial infarction;
STEMI, ST-segment elevation myocardial infarction; and UA, unstable
angina
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afford unique and valuable insights into treatment effective-
ness and generalisability in routine practice [10]. In this re-
gard, multiple registries have demonstrated the underuse of
evidence-based medical therapies at discharge among patients
with ACS, irrespective of geographic location [11–15]. In
these studies, 16–90 % received aspirin at hospital discharge,
17–70 % thienopyridines, 60–81 % ACE-I/ARBs, 50–90 %
β-blockers, and 70–84 % statins. The collective use rates of
these pharmacological agents ranged from 46 % to 51 %. The
present study indicates that both individual and collective use
rates of these agents in ACS patients at discharge were rea-
sonably high in our region compared with aforementioned
registries [11–15].
The use of thienopyridines marginally decreased from
99.8 % at discharge to 99.1 % at 1-month follow-up corre-
sponding to a total number of 7 patients discontinuing therapy.
Nevertheless, this reached statistical significance (McNemar
p =0.02). Although the exact reasons for discontinuing med-
ications during this period are not clear, potential factors,
including adverse side effects or patient compliance may
constitute barriers to continuation of therapy. Of note, the 7
patients discontinuing thienopyridine therapy received either
aspirin or oral anticoagulants during follow-up.
Despite the encouraging utilisation rates of 5-class combina-
tion treatment at discharge and follow-up in the present study,
there is still room for improvement when considering that all
Fig. 2 Institutional discharge prescription rates. ACE-I/ARB indicates angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker
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centres should reach the same level as the top 3 (Figs. 2 and 3).
However, it is important to note that the absence of one of the 5
classes of pharmacological agents after ACS does not necessar-
ily imply that patients are not treated optimally. Practice guide-
lines recommend the use of these agents in all patients with
ACS, unless contraindicated [3, 4, 6]. For instance, significant
bradycardia (heart rate <50 beats/min) or hypotension (systolic
blood pressure <90 mmHg) are contraindications to β-blockers.
ACE-I are indicated in all patients with STEMI and NSTE-ACS
patients with left ventricular ejection fraction ≤40 %, heart
failure, diabetes, hypertension, or chronic kidney disease, how-
ever, in the absence of severe renal dysfunction (serum creati-
nine >221 μmol/l in men or >177 μmol/l in women) [3, 4].
Thus, patients receiving a combination of all indicated therapies
are optimally treated from a clinical perspective.
Several investigators have studied the determinants of in-
dividual medication use after ACS [11, 12, 16–18]. The
current report builds on prior work by demonstrating that
UA was also independently associated with lower use of
combination therapy at discharge, along with the previously
reported negative predictor advanced age. In contrast, patients
presenting with STEMI, hypertension, hypercholesterolaemia
and those enrolled to the registry in an interventional centre
were more likely to be given optimal medical treatment.
Recommendations from the European Society of Cardiology
guidelines stress the importance of the development of regional
Fig. 3 Institutional follow-up prescription rates. ACE-I/ARB indicates angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker
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and/or national programs to measure performance indicators
systematically that can provide feedback to individual hospitals
[3]. In accordance with these recommendations, the Netherlands
Society of Cardiology (NVVC) has developed core competen-
cies that recognise the important role of quality improvement for
themanagement of ACS (that is, the ‘NVVC!Connect’ project).
In this regard, the CCR registry serves as an ideal model for
implementation and follow-up of measures aimed to improve
institutional compliance with national quality standards.
Moreover, it exemplifies a collaborative study design that em-
ploys a regional PCI registry platform, potentially enhancing
hospital care quality in the context of an actively enrolling
research study. In response to the current observations, the
regional ‘NVVC! Connect’ committee will launch several ini-
tiatives to improve compliance with medical management rec-
ommendations from the ESC guidelines. Of note, pre-hospital
care [19], rapid identification and risk stratification [20] of these
patients are particularly relevant to this concept, because these
represent equally important core competencies for effective care
likely improving secondary prevention after ACS.
The current results provide a baseline measurement for
discharge management of ACS in our region, and adherence
at 1-month follow-up. Although initiation of evidence-based
therapies after discharge is encouraging, numerous studies
have documented the rapid decline in adherence to medica-
tions after hospitalisation for ACS [21, 22]. For this reason,
we will perform a subsequent measurement at the end of the
registry when the intended number of 4000 patients is recruit-
ed. Consequently, this will provide essential information re-
garding patient adherence to evidence-based pharmacological
therapies at 1-year follow-up, as previously demonstrated in
the Dutch MISSION! study [19]. On the other hand, we will
also compare the current results with data from the following
consecutive three subsets of 1000 patients. This will provide
an important evaluation of patient management over time and
will ascertain whether a quality gap exists in our region. This
in turn may lead to new processes that help institutions meet
benchmarks of quality care. More importantly, we will exam-
ine the relationship between the collective use of these agents
and 1-month and 1-year outcome at the end of the registry.
The current study has several limitations that deserve com-
ment. First, we did not collect detailed information on contra-
indications to medications. However, we assume that patient
profiles were evaluated before institution of agents and other
reasons for withholding medical therapy were probably un-
common. Second, adherence to medication was assessed at
1-month follow-up. Use rates of pharmacological agents at
1-year follow-up may vary due to discontinuation and initia-
tion of treatment after discharge. We will address this issue at
the end of the registry when the 1-year follow-up is complete.
Conclusion
The present individual and collective utilisation rates of
guideline-recommended pharmacological therapies indicate
that current discharge management after ACS is of substantial
quality in our registry and region. However, despite high rates
of use, there is still potential for quality improvement of
medical management of these patients. Importantly, the CCR
registry will continue to provide essential data concerning
regional performance and will potentially enhance hospital care
quality in the context of an actively enrolling research study.
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Appendix
Participating centres Albert Schweitzer Hospital, Dordrecht; Beatrix
Hospital, Gorinchem; Erasmus MC Rotterdam; Havenziekenhuis,
Rotterdam; IJsselland Hospital, Rotterdam; Ikazia Hospital, Rotterdam;
Maasstad Hospital, Rotterdam; Ruwaard van Putten Hospital, Spijkenisse;
Sint Franciscus Gasthuis, Rotterdam; Van Weel-Bethesda Hospital,
Dirksland; and Vlietland Hospital, Schiedam. All centres are in the
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